In this regard one of the major determinants of the VTE risk in HGG is the presence or absence of isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations, with wild type IDH1/2 status identifying procoagulant glioblastomas (GBMs) and IDH1/2 (R132H) mutation associated with a relatively non-coagulant presentation (47). This evidence concerns the gene IDH1 and glioblastoma.